Jaguar Health, Inc. (JAGX)

Over the past six months, Jaguar Health, Inc.'s stock price has significantly declined. The Q3 2025 earnings report missed analysts' estimates, impacting the stock. Jaguar Animal Health secured a note agreement, and Jaguar Health completed a private placement deal. The company received FDA grants to fund a trial for Canalevia. Jaguar Health entered into a license agreement with Future Pak for crofelemer. Shares of Jaguar Animal Health underwent a reverse stock split.

The provided information does not explicitly mention demand seasonality for Jaguar Health, Inc.'s products and services. As a pharmaceutical company focusing on chronic conditions, it is less likely to experience significant seasonal fluctuations in demand compared to consumer goods. The demand for prescription medicines for ongoing health conditions typically remains relatively stable throughout the year.

Jaguar Health, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing plant-based prescription medicines for gastrointestinal distress in humans and animals. Their core product, Mytesi, is an FDA-approved drug for non-infectious diarrhea in adults with HIV/AIDS. They are also developing crofelemer for chemotherapy-induced overactive bowel and expanding access in Europe for orphan and rare diseases through Napo Therapeutics. Jaguar Animal Health focuses on products for enteric disorders in animals, and Magdalena Biosciences is a joint venture for plant-derived mental health medicines.

Jaguar Health, Inc. is headquartered in San Francisco, California, United States. The company is expanding its geographic reach through its Italian subsidiary, Napo Therapeutics, established in Milan to increase crofelemer access in Europe, particularly for orphan and rare diseases.

Jaguar Health's brand reputation is mixed, with positive developments in its clinical pipeline and strategic focus, alongside stock underperformance. The company is considered a pioneering pharmaceutical company with a unique value proposition. Analyst recommendations suggest a strong buy for growth-oriented investors. However, the stock has underperformed the US Pharmaceuticals industry and the broader US Market. The company has frail financial strength and relatively risky volatility. Positive news releases regarding FDA grants and licensing agreements could positively impact reputation.

Jaguar Health, Inc. has institutional owners and shareholders holding a total of 104,307 shares. Institutional investors own 12.04% of the stock. The general public holds a significant portion of the shares, and insiders also own shares in the company.